Alpha 2.0
Login Register
» Articles » PMID: 32548660

Bortezomib and Rituximab in Multiply Relapsed Primary Warm Autoimmune Hemolytic Anemia

Overview
Journal Ann Hematol
Specialty Hematology
Date 2020 Jun 18
PMID 32548660
Citations 5
Authors
Paul R J Ames
Susan Jeffrey
Affiliations
Soon will be listed here.
Citing Articles

Successful Management of Severe and Refractory Autoimmune Hemolytic Anemia (AIHA) in a Sickle Cell Disease Patient With Bortezomib.

Alanssari M, Al-Sulaitti E, Al-Sulaitti Z, Khalaf A, Dawood Q Cureus. 2024; 16(11):e74840.

PMID: 39737253 PMC: 11684491. DOI: 10.7759/cureus.74840.

The Role of the Spleen and the Place of Splenectomy in Autoimmune Hemolytic Anemia-A Review of Current Knowledge.

Cvetkovic Z, Pantic N, Cvetkovic M, Virijevic M, Sabljic N, Marinkovic G Diagnostics (Basel). 2023; 13(18).

PMID: 37761258 PMC: 10527817. DOI: 10.3390/diagnostics13182891.

Development of New Drugs for Autoimmune Hemolytic Anemia.

Xiao Z, Murakhovskaya I Pharmaceutics. 2022; 14(5).

PMID: 35631621 PMC: 9147507. DOI: 10.3390/pharmaceutics14051035.

Bortezomib in autoimmune hemolytic anemia and beyond.

Pasquale R, Giannotta J, Barcellini W, Fattizzo B Ther Adv Hematol. 2021; 12:20406207211046428.

PMID: 34795889 PMC: 8593301. DOI: 10.1177/20406207211046428.

New Insights in Autoimmune Hemolytic Anemia: From Pathogenesis to Therapy Stage 1.

Barcellini W, Zaninoni A, Giannotta J, Fattizzo B J Clin Med. 2020; 9(12).

PMID: 33261023 PMC: 7759854. DOI: 10.3390/jcm9123859.